Proof of Biological Activity of SAR100842 in Systemic Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: July 24, 2012
Last updated: June 16, 2014
Last verified: June 2014

Primary Objective:

- To evaluate safety and tolerability of 8-week oral administration of SAR100842 in patients with diffuse, cutaneous systemic sclerosis.

Secondary Objectives:

  • To evaluate the pharmacodynamic effect of SAR100842 in patients with systemic sclerosis as measured by disease related biomarkers and Lysophosphatidic acid (LPA) receptor signaling markers in blood and skin
  • To explore the effect of SAR100842 on skin thickness in patients with systemic sclerosis as measured by the Modified Rodnan Skin score (mRSS)
  • To explore the effect of SAR100842 on quality of life as measured by the Scleroderma Modified Health Assessment Questionnaire (SHAQ).

Condition Intervention Phase
Systemic Sclerosis
Drug: SAR100842
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled, 8-week Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Safety and tolerability during the 8 week treatment period (Number of patients reporting adverse events) [ Time Frame: Up to 8 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacodynamic changes from baseline to End of Treatment Visit in biomarkers obtained from blood and skin [ Time Frame: at Day 1 and 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to End of Treatment Visit in skin severity score (mRSS) and in Scleroderma health assessment questionnaire (SHAQ) [ Time Frame: at Day 1 and 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: January 2013
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SAR100842
Oral administration, twice daily, every day, for 8 weeks
Drug: SAR100842

Pharmaceutical form:tablets

Route of administration: oral

Placebo Comparator: Placebo
Oral administration, of matching pills, twice daily, every day, for 8 weeks
Drug: Placebo

Pharmaceutical form:tablets

Route of administration: oral

Detailed Description:
Each patient's participation in the study will be approximately 13 weeks: up to 2 weeks of screening, 8 weeks of treatment and 3 weeks of follow up

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria :

- Patients who meet the American College of Rheumatology (ACR) criteria for systemic sclerosis with diffuse cutaneous involvement and <36 months since the onset of the first systemic sclerosis manifestation other than Raynaud's phenomenon and have a Modified Rodnan Skin Score (mRSS) ≥ 15 and an area of definite involvement of the dorsal forearm that is considered amenable to repeated 4mm skin biopsies.

Exclusion criteria:

  1. Patients with high dose or unstable low dose immunosuppressive drugs, cytotoxic, anti-fibrotic or glucocorticoids drugs at least 4 weeks prior to screening
  2. Serum creatinine > 2.0 mg/dL
  3. Gastrointestinal involvement preventing oral administration of study drug
  4. Severe cardiac and/or pulmonary disease

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01651143

United States, Arizona
Investigational Site Number 840006
Scottsdale, Arizona, United States, 85259-5499
United States, District of Columbia
Investigational Site Number 840003
Washington, District of Columbia, United States, 20007
United States, Maryland
Investigational Site Number 840004
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Investigational Site Number 840001
Boston, Massachusetts, United States, 02118
United States, Michigan
Investigational Site Number 840002
Ann Arbor, Michigan, United States, 48106
United States, New Jersey
Investigational Site Number 840007
New Brunswick, New Jersey, United States, 08903
United States, Pennsylvania
Investigational Site Number 840008
Pittsburgh, Pennsylvania, United States, 15213
Investigational Site Number 250003
Lille, France, 59037
Investigational Site Number 250001
Paris Cedex 14, France, 75679
Investigational Site Number 380001
Milano, Italy, 20122
Investigational Site Number 756001
Zürich, Switzerland, 8091
United Kingdom
Investigational Site Number 826001
London, United Kingdom
Investigational Site Number 826002
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

No publications provided

Responsible Party: Sanofi Identifier: NCT01651143     History of Changes
Other Study ID Numbers: ACT12339  2012-001369-34  U1111-1127-2854 
Study First Received: July 24, 2012
Last Updated: June 16, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Scleroderma, Diffuse
Scleroderma, Systemic
Connective Tissue Diseases
Pathologic Processes
Skin Diseases processed this record on February 07, 2016